Literature DB >> 21276605

Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Walter Kinney1, Barbara Fetterman, J Thomas Cox, Thomas Lorey, Tracy Flanagan, Philip E Castle.   

Abstract

OBJECTIVE: To characterize the cervical cancers diagnosed following a Pap-negative, high risk human papillomavirus (HPV)-positive (Pap-/HPV+) screen in routine clinical practice.
METHODS: Using data from Kaiser Permanente Northern California, we investigated the cases of cervical cancer diagnosed between January, 2003 and January, 2009 following Pap-/HPV+ screen. Two cervical specimens were routinely collected for cervical cancer screening, one for conventional cytology and the other for high risk HPV testing using Hybrid Capture 2 (Qiagen).
RESULTS: Forty-four women (median age at diagnosis=44years) were diagnosed with primary invasive cervical cancer with a recent history of one or more Pap-/HPV+ screens. Twenty-six women had one Pap-/HPV+ screen preceding the diagnosis of cancer, 15 had two, and three had three. There were 16 squamous cancers, one small cell cancer, 24 adenocarcinomas, 2 adenosquamous carcinomas, and one case with separate invasive squamous and adenocarcinoma. FIGO Stage was IA in 11 women, IB in 31 women and IIA in 2 women. Treatment included a pelvic node dissection in 30, 2 (6.7%) of whom had positive nodes.
CONCLUSIONS: HPV testing contributes to early cervical cancer diagnosis detection in women with negative Pap tests. Most women in this cohort have early stage, node negative, treatable and potentially curable disease. Adenocarcinoma predominated as might be expected because cytology misses these cancers and their precursors. The majority of cancers were diagnosed following a single Pap-/HPV+ screen, suggesting that effective triage to colposcopy of women with a Pap-/HPV+ screen would be preferable to retesting in one year as currently recommended.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21276605      PMCID: PMC3081890          DOI: 10.1016/j.ygyno.2010.12.361

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  41 in total

1.  Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities.

Authors:  Diane Solomon; Mark Stoler; Jose Jeronimo; Michelle Khan; Philip Castle; Mark Schiffman
Journal:  Obstet Gynecol       Date:  2007-08       Impact factor: 7.661

2.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Authors:  Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

3.  The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology.

Authors:  Mark E Sherman; Abhijit Dasgupta; Mark Schiffman; Ritu Nayar; Diane Solomon
Journal:  Cancer       Date:  2007-02-25       Impact factor: 6.860

4.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

Review 5.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

Authors:  Marc Arbyn; Peter Sasieni; Chris J L M Meijer; Christine Clavel; George Koliopoulos; Joakim Dillner
Journal:  Vaccine       Date:  2006-08-31       Impact factor: 3.641

6.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

Authors:  Jack Cuzick; Christine Clavel; Karl-Ulrich Petry; Chris J L M Meijer; Heike Hoyer; Samuel Ratnam; Anne Szarewski; Philippe Birembaut; Shalini Kulasingam; Peter Sasieni; Thomas Iftner
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

7.  Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix.

Authors:  Sok Cheon Pak; Martje Martens; Ruud Bekkers; Alex J Crandon; Russell Land; James L Nicklin; Lewis C Perrin; Andreas Obermair
Journal:  Aust N Z J Obstet Gynaecol       Date:  2007-12       Impact factor: 2.100

8.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

9.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

10.  Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.

Authors:  Guglielmo Ronco; Jack Cuzick; Paola Pierotti; Maria Paola Cariaggi; Paolo Dalla Palma; Carlo Naldoni; Bruno Ghiringhello; Paolo Giorgi-Rossi; Daria Minucci; Franca Parisio; Ada Pojer; Maria Luisa Schiboni; Catia Sintoni; Manuel Zorzi; Nereo Segnan; Massimo Confortini
Journal:  BMJ       Date:  2007-05-21
View more
  10 in total

Review 1.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

2.  Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

3.  Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis.

Authors:  Lea A Moukarzel; Ana M Angarita; Christopher VandenBussche; Anne Rositch; Carol B Thompson; Amanda N Fader; Kimberly Levinson
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

4.  Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Authors:  Theodoros Agorastos; Kimon Chatzistamatiou; Taxiarchis Katsamagkas; George Koliopoulos; Alexandros Daponte; Theocharis Constantinidis; Theodoros C Constantinidis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

5.  Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Authors:  Rong Wang; Robert W van Leeuwen; Aniek Boers; Harry G Klip; Tim de Meyer; Renske D M Steenbergen; Wim van Criekinge; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman
Journal:  Oncotarget       Date:  2016-12-06

Review 6.  Detection of Host Cell Gene/HPV DNA Methylation Markers: A Promising Triage Approach for Cervical Cancer.

Authors:  Lingyi Zhang; Wenxi Tan; Hongmei Yang; Songling Zhang; Yun Dai
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

7.  Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.

Authors:  Sonya Naryshkin; R Marshall Austin
Journal:  Drug Healthc Patient Saf       Date:  2012-11-02

8.  Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.

Authors:  M K Leinonen; A Anttila; N Malila; J Dillner; O Forslund; P Nieminen
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

9.  Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis.

Authors:  Rachel D Conrad; Angela H Liu; Nicolas Wentzensen; Roy R Zhang; S Terence Dunn; Sophia S Wang; Mark Schiffman; Michael A Gold; Joan L Walker; Rosemary E Zuna
Journal:  Cancer Cytopathol       Date:  2018-10-23       Impact factor: 5.284

10.  Effects of an Additional Liquid Based Cytology Prepate on Cytological Diagnosis in High-Risk HPV Positive, PaP Test Negative Cases.

Authors:  Davut Şahin; Nermin Koç; Meryem Akbaş
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2019-12-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.